ESC Premium Access

Hemoglobin, anemia, and clinical outcomes in vericiguat global study in subjects with heart failure with reduced ejection fraction (VICTORIA)

Congress Session

About the speaker

Professor Justin Ezekowitz

University of Alberta, Edmonton (Canada)
6 presentations
0 follower

46 more presentations in this session

Impact of changes in weight and haematocrit on the reduction in systolic office and ambulatory blood pressure with empagliflozin in patients with type 2 diabetes

Speaker: Doctor A. Sharma (Montreal, CA)

Thumbnail

SGLT-2 inhibitors in patients with and without a history of heart failure: a meta-analysis

Speaker: Doctor V. Razuk (New York, US)

Thumbnail

Cardiovascular outcome in patients treated with SGLT2 inhibitors for heart failure: a meta-analysis

Speaker: Doctor G. Gager (Vienna, AT)

Thumbnail

Reduced tissue sodium content is related to improvement of vascular function in patients with chronic heart failure treated with the SGLT2 inhibitor empagliflozin

Speaker: Doctor J. Kolwelter (Erlangen, DE)

Thumbnail

Efficacy and safety of vericiguat in patients with HFrEF treated with sacubitril/valsartan: results from the VICTORIA trial

Speaker: Doctor M. Senni (Bergamo, IT)

Thumbnail

Access the full session

Congress committee e-posters choice in heart failure

Speakers: Professor J. Ezekowitz, Doctor A. Sharma, Doctor V. Razuk, Doctor G. Gager, Doctor J. Kolwelter...
Thumbnail

About the event

Image

ESC Congress 2021 - The Digital Experience

27 August - 30 August 2021

Sessions Presentations

Related content

ESC Premium Access

A closer look at heart failure drugs: particular benefits and problems.

27 August 2021

ESC Premium Access

The practicalities of drug treatment in heart failure - Chat Moderator.

27 August 2021

ESC Premium Access

Cardiovascular protection by combination of the selective nonsteroidal MR antagonist finerenone and the SGLT2 inhibitor empagliflozin in a preclinical model of hypertension-induced end-organ damage

27 August 2021

This platform is supported by

logo Novo Nordisk